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According to the disease control and prevention data of 
China, hepatitis B vaccinations have caused 188 coinci-
dence deaths of newborns totally from 2000 to 2013. No 
problems have been found with the vaccines. Besides in-
spection of the manufacturers, all vaccines are launched to 
the market after inspection of the central government of 
China. Similar events happened also in other vaccines. The 
recent deaths related to hepatitis B vaccination have been 
proved to be coincidence. The hepatitis B virus vaccine 
used is originally jointly developed by the Chinese govern-
ment and the US government. Its safety has been proved by 
the inoculation of one billion people around the globe. 
Vaccines are major means for epidemic control. In 2009, 
during the new influenza A (H1N1) pandemic originating 
from Mexico, under the leadership of inter-departmental 
and inter-regional mechanisms for joint prevention and con-
trol, China implemented nationwide collaborative innova-
tion, producing safe and effective vaccines within 87 days, 
which are unprecedented in the world, and inoculating 105 
million people all over the country. Research showed that 
the protection rate of H1N1 vaccine reached 87.3%, and 
China has established an inspection system for vaccine 
safety covering 70 million inoculated people, demonstrating 
the vaccines are safe and the Guillain-Barre syndrome has 
nothing to do with H1N1 vaccines. Moreover, it demon-
strated for the first time that one dose of the vaccine is able 
to give effective protection. On 21 August 2009, Chen Zhu, 
the former minister of Ministry of Health of China, for the 
first time announced the aforementioned research results to 
the world in an international conference organized by  
Lancet in Beijing. Evaluation given by a third party, Tsing-
hua University, said that the timely production of the vac-
cine has been critical to the control of the pandemic, reduc-
ing 250 million infections and hospitalization of 69500 
people. 
In 1992, the hepatitis B surface antigen carries in China 
accounted for 9.75% of the Chinese population, making 
China a big country with a large population carrying hepati-
tis. On 1 January 1992, China implemented the hepatitis B 
immunization program; investigation in 2006 showed that 
the hepatitis B surface antigen carrier rate in the country has 
decreased to 7.18%. This rate among children under five 
years old has been reduced to less than 0.5%, meeting the 
requirement of the World Health Organization Western Pa-
cific Region three years in advance. 
In 2008, China included the prevention and control of 
viral hepatitis in a major science and technology project 
titled “Prevention and Treatment of AIDS and Viral Hepati-
tis and Other Major Infectious Diseases”. During the 
“Eleventh Five-year Plan”, researchers discovered that the 
non-response and low-response rates of 5 µg hepatitis B 
vaccine were relatively high, and changed it to 10 µg, which 
was used in the widespread inoculation of 15-year-old 
teenagers in China in 2012. Afterwards, the high-dose vac-
cines of 20 and 60 µg have been successfully developed. 
The plan for adult immunization has been carried out in the 
model area of the major science and technology project. It is 
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believed that China will soon get rid of its title as a big 
country with a large population carrying hepatitis B, and the 
Chinese people will no longer have to suffer from this dis-
ease in the near future.
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